日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Distant recurrence and margin involvement in invasive breast cancer

浸润性乳腺癌的远处复发和切缘受累

Michael, Sarah; Broggio, John; Bowers, Sarah; Ooi, Jane; Armstrong, Anne; Absar, Mohammed; Dimipoulos, Nikitas; Ellenbogen, Simon; Gath, Jacqui; Martin, Glen; Bundred, Nigel James

Patient-Derived Procoagulant Breast Fibroblasts Expressing Tissue Factor Promote Breast Cancer Cell Migration.

表达组织因子的患者来源的促凝血乳腺成纤维细胞促进乳腺癌细胞迁移。

Ogunlayi Hadiyat A, Castle John, Blower Emma L, Armstrong Anne, Clarke Robert B, Kirwan Cliona C

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

BRCA1 和 BRCA2 相关乳腺癌的新辅助 PARP 抑制剂治疗方案:PARTNER,一项随机 II/III 期试验

Abraham Jean E, O'Connor Lenka Oplustil, Grybowicz Louise, Alba Karen Pinilla, Dayimu Alimu, Demiris Nikolaos, Harvey Caron, Drewett Lynsey M, Lucey Rebecca, Fulton Alexander, Roberts Anne N, Worley Joanna R, Chhabra Ms Anita, Qian Wendi, Brown Jessica, Hardy Richard, Vallier Anne-Laure, Chan Steve, Cidon Maria Esther Una, Sherwin Elizabeth, Chakrabarti Amitabha, Sadler Claire, Barnes Jen, Persic Mojca, Smith Sarah, Raj Sanjay, Borley Annabel, Braybrooke Jeremy P, Staples Emma, Scott Lucy C, Palmer Cheryl A, Moody Margaret, Churn Mark J, Pilger Domenic, Zagnoli-Vieira Guido, Wijnhoven Paul W G, Mukesh Mukesh B, Roylance Rebecca R, Schouten Philip C, Levitt Nicola C, McAdam Karen, Armstrong Anne C, Copson Ellen R, McMurtry Emma, Galbraith Susan, Tischkowitz Marc, Provenzano Elena, O'Connor Mark J, Earl Helena M

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1

卡美司群联合三种全球获批的 CDK4/6 抑制剂治疗 ER+、HER2- 晚期乳腺癌女性患者:SERENA-1 研究结果

Baird, Richard D; Bermejo de Las Heras, Begoña; Ruiz-Borrego, Manuel; Vaklavas, Christos; Moreno, Irene; Oliveira, Mafalda; Armstrong, Anne; Turner, Nicholas; Incorvati, Jason; Twelves, Chris; Ciruelos, Eva; Hamilton, Erika; Patel, Manish R; Kabos, Peter; Ciardullo, Carmela; Klinowska, Teresa; Lindemann, Justin P O; Mathewson, Alastair M; Morrow, Christopher J; Sykes, Andy; Yang, Jincheng; Zhang, Bairu; Victoria, Ivan

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer

H3B-6545治疗局部晚期/转移性雌激素受体阳性、HER2阴性乳腺癌女性患者的I/II期研究

Hamilton, Erika; Pluard, Timothy; Wang, Judy S; Morikawa, Aki; Johnston, Stephen; Dees, E Claire; Vaklavas, Christos; Armstrong, Anne; Munster, Pamela; Unni, Nisha; Wright, Gail S; Kayali, Fadi; Song, Tingting; Rong, Yuanxin; Yamaguchi, Kohei; Juric, Dejan

Management of menopausal symptoms following treatment for hormone receptor positive breast cancer

激素受体阳性乳腺癌治疗后更年期症状的管理

McGrath, Sophie; Pomeranc, Abigail; Karmali, Yusuf; Taylor, Sarah; Morgan, Adrienne; Turner, Lesley; Armstrong, Anne

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

OlympiA 研究的患者报告结局:一项针对 gBRCA1/2 突变和高危人表皮生长因子受体 2 阴性早期乳腺癌患者的奥拉帕尼辅助治疗 III 期随机、安慰剂对照试验

Ganz, Patricia A; Bandos, Hanna; Španić, Tanja; Friedman, Sue; Müller, Volkmar; Kuemmel, Sherko; Delaloge, Suzette; Brain, Etienne; Toi, Masakazu; Yamauchi, Hideko; de Dueñas, Eduardo-M; Armstrong, Anne; Im, Seock-Ah; Song, Chuan-Gui; Zheng, Hong; Sarosiek, Tomasz; Sharma, Priyanka; Geng, Cuizhi; Fu, Peifen; Rhiem, Kerstin; Frauchiger-Heuer, Heike; Wimberger, Pauline; t'Kint de Roodenbeke, Daphné; Liao, Ning; Goodwin, Annabel; Chakiba-Brugère, Camille; Friedlander, Michael; Lee, Keun Seok; Giacchetti, Sylvie; Takano, Toshimi; Henao-Carrasco, Fernando; Virani, Shamsuddin; Valdes-Albini, Frances; Domchek, Susan M; Bane, Charles; McCarron, Edward C; Mita, Monica; Rossi, Giovanna; Rastogi, Priya; Fielding, Anitra; Gelber, Richard D; Scheepers, Elsemieke D; Cameron, David; Garber, Judy; Geyer, Charles E; Tutt, Andrew N J

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

紫杉醇联合可溶性 LAG-3 蛋白 Eftilagimod Alpha 治疗转移性 HR+ 乳腺癌:AIPAC 随机、安慰剂对照 IIb 期试验的结果

Wildiers, Hans; Armstrong, Anne; Cuypere, Eveline; Dalenc, Florence; Dirix, Luc; Chan, Steve; Marme, Frederik; Schröder, Carolina P; Huober, Jens; Duhoux, Francois P; Vuylsteke, Peter; Jager, Agnes; Brain, Etienne; Kuemmel, Sherko; Pápai, Zsuzsanna; Menke-van der Houven van Oordt, Catharina Willemien; Perjesi, Luca; Mueller, Christian; Brignone, Chrystelle; Triebel, Frederic

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

乳腺癌患者术后循环肿瘤DNA连续检测在长期随访中具有很强的预后价值

Shaw, Jacqueline A; Page, Karen; Wren, Evie; de Bruin, Elza C; Kalashnikova, Ekaterina; Hastings, Robert; McEwen, Rob; Zhang, Eddie; Wadsley, Marc; Acheampong, Emmanuel; Renner, Derek; Gleason, Kelly L T; Ambasager, Bana; Stetson, Daniel; Fernandez-Garcia, Daniel; Guttery, David; Allsopp, Rebecca C; Rodriguez, Angel; Zimmermann, Bernhard; Sethi, Himanshu; Aleshin, Alexey; Liu, Minetta C; Richards, Cathy; Stebbing, Justin; Ali, Simak; Rehman, Farah; Cleator, Susan; Kenny, Laura; Ahmed, Samreen; Armstrong, Anne C; Coombes, R Charles

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

OlympiAD 研究延长了总生存期和安全性随访时间:奥拉帕尼与医生选择的化疗方案在携带胚系 BRCA 突变且 HER2 阴性转移性乳腺癌患者中的疗效比较

Robson, Mark E; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco